Respiratory Syncytial Virus (RSV) Vaccine Acceptance Among the Elderly in Al-Qassim Region, Saudi Arabia Authors: Moath Aljohani, Dawood Al-Oraini Published: 2026 ABSTRACT ObjectiveThe Respiratory Syncytial Virus (RSV) vaccine has recently been introduced in Saudi Arabia for adults aged 60 and older. There are limited published studies on this topic in Saudi Arabia for this age group. This study aimed to assess RSV vaccine acceptance among older adults in the Al-Qassim region of Saudi Arabia.MethodsThe data were collected via online forms that invited participants aged 60 years and older, living in the Al-Qassim region, to participate. The study tool included items related to sociodemographic variables, chronic disease history, knowledge of the RSV disease, and perceived susceptibility and severity. In addition to previous RSV uptake and willingness to vaccinate, along with previous vaccination history for other indicated vaccines such as herpes zoster, Influenza, and Pneumococcal.Results341 responses met the inclusion criteria. The majority of participants were aged < 70 years (74.5%), males (57.5%), and 38.1% had a university education or higher. 67.7% had at least one chronic disease, with diabetes being the most common (41.8%). The majority (83.6%) have never heard of RSV. Only 5 (1.5%) respondents reported prior uptake, while 16.1% demonstrated RSV acceptance overall. The most prominent facilitator among vaccine-acceptant individuals was physician or healthcare professional recommendation (45.5%). The most cited barriers among vaccine-hesitant or undecided individuals (n=286) were the perception of the RSV vaccine as “a new vaccine” (50.0%) and concerns about vaccine safety and effectiveness (44.1% and 26.2%, respectively). Only higher uptake of other indicated vaccines showed a significant association with vaccine acceptance (aOR 1.575, 95% CI 1.220–2.033, p < 0.001).ConclusionThe study demonstrated very low vaccine uptake and willingness, with reported barriers like concerns about the vaccine’s recent introduction and uncertainty about its safety and effectiveness. Efforts tailored to educate the elderly about the vaccine’s importance, safety, and effectiveness are needed to improve vaccine uptake. Introduction Respiratory syncytial virus (RSV) is a viral infection associated with significant morbidity and mortality.1 It can cause a wide range of severity, from a simple upper respiratory tract infection to severe pneumonia.2 The RSV can cause severe disease and death among age extremes, including children who are below the age of 6 months and the elderly with associated comorbidities.1 RSV-associated acute lower respiratory tract infection causes more than three million hospitalizations, more than 100,000 deaths among children younger than 5 years, and nearly half of these deaths are among those aged 6 months or less. Most pediatric age RSV-associated deaths occur in low- and middle-income countries, where the availability of supportive medical care is hindered by the economic capabilities of the countries.3 However, a specific estimate of RSV’s global impact on adults is not yet available. In the United States of America, it has been estimated that RSV results in more than 150,000 hospital admissions and 10,000 deaths among adults over 65 years of age.1 Higher hospitalization risk was among those with existing comorbid conditions, like asthma, chronic obstructive pulmonary disease, and heart failure, where RSV worsens the underlying condition.4 Regarding the seasonal circulation of the virus, most countries exhibit a seasonal pattern in which most cases occur over five months, consistent with elevated viral circulation, with epidemics tending to occur during late fall.1,5,6 In Saudi Arabia, the RSV season is considered to last from the middle of October to the middle of March.7 RSV is transmitted like other respiratory infections, including direct transmission of infectious particles released from infected individuals when they cough or sneeze, or through contact with contaminated surfaces.1,8 Symptoms usually appear within a week and, in most cases, include upper respiratory tract infection symptoms, while in more severe cases, it can show signs of lower respiratory tract infections, such as pneumonia, with symptoms such as shortness of breath, cough, wheezing, and bronchospasm.1 It is associated with 10.6% of pneumonia-associated hospitalizations among the elderly, and has a considerable contribution to the burden of Asthma, heart failure and chronic obstructive pulmonary disease.9 Management of RSV severe cases usually involves supportive care, such as hydration and supplemental oxygen.1,2 In order to prevent severe RSV disease, several RSV vaccines have been developed to protect children and older adults.10 For infants, one approach is maternal vaccination during the third trimester, which allows maternal antibodies to be transmitted to the neonate and provides protection during the most critical period, as the first six months of life.10 Another approach is through immunization with monoclonal antibodies for all neonates before their first RSV season or children up to 2 years of age who are at risk of severe illness.1,10 Vaccines were approved for adults in 2023. In the US, adult vaccines are indicated for older adults aged 75 and older or adults aged 50 to 74 with an increased risk of severe infection, such as those with chronic cardiovascular, respiratory, renal, or liver diseases, as well as diabetic patients with existing complications, among others.11 The vaccine effectiveness was 77% against RSV-associated emergency department visits, 80% against RSV hospitalizations among immunocompetent individuals, and 73% among immunocompromised individuals.12 Although effective vaccines exist, challenges to vaccine acceptance, such as vaccine hesitancy, persist. The WHO has identified vaccine hesitancy as one of the top ten global threats to global health, defined as the reluctance or refusal to receive a vaccine despite its availability.13 The RSV vaccination program has been implemented recently in Saudi Arabia and other Arab countries. The program was launched in 2024 for older adults aged 60 years and older.14 A retrospective study in Saudi Arabia shows that around one out of every four patients with RSV community-acquired pneumonia was admitted to the ICU, and among those, the mortality approached 32%; the majority were elderly with comorbidities.15 Given this risk, the Saudi Thoracic Society guidelines recommend RSV vaccination for individuals aged 60 years and older with chronic respiratory disease.16 Few studies reported RSV vaccine acceptance and uptake among the Saudi population and Arab countries in general. For example, one study included participants from different Arab countries, which showed that 26.5% refused, 22.4% were hesitant, and 51.1% accepted the vaccine. Among the Saudi sample, 70.6% accepted the vaccine, 21.6% were hesitant or neutral, and 7.8% refused vaccination.17 However, the study included a few participants from Saudi Arabia aged 50 and older, limiting the generalizability of its findings to the Saudi elderly and not reflecting the current indication for vaccines for adults aged 60 years and older. Additionally, despite the earlier introduction of the RSV vaccine for pregnant women compared to the elderly, the sample of postpartum women revealed that 51% had previous awareness of RSV infection, and 58% showed acceptance for the antenatal RSV vaccine.18 This study aimed to determine the RSV vaccine acceptance among a sample of the elderly in the Al-Qassim Region of Saudi Arabia. Materials and Methods In the current study, we used a cross-sectional design and collected data between November 2025 and April 2026. Data collection followed non-probability snowball sampling, with the survey link circulated via WhatsApp by study investigators through friends, family networks, and community groups to reach the target population in the Al Qassim region of Saudi Arabia, allowing participants themselves or their family members to respond to the questionnaire on behalf of an eligible older adult parent (proxy reporting). The inclusion criteria were being Arabic-speaking, 60 years old or older, and residing in the Al Qassim region of Saudi Arabia. Sample size calculation was conducted based on the assumption of a 95% confidence interval, a margin of error of 5%, and an expected RSV acceptance of 51.1%.17 The calculated sample size was 384. The data collection tool was based on a self-administered survey consisting of several sections. At first, the title page was shown to participants, including the study title, purpose, time needed to respond, ethical approval data, the contact information of the study investigators, and the invitation to participate in the study for those fitting the inclusion criteria. Additionally, we asked respondents not to participate again if they had previously responded to this survey to prevent duplicate responses. Responses to items were mandatory to reduce incompleteness; some sections related to facilitators of vaccination were not shown for non-vaccine acceptors and vice versa. Additionally, the questionnaire items allowed for the options of undecided or lacking the exposure of interest, like “I did not receive any vaccine” or “I do not have any chronic disease”, “ unsure” and “do not know” to allow for more accurate and representative responses. The first section of the questionnaire included demographics and chronic disease history data. These include age in years, sex, educational status ranging from elementary or below to higher education as a PhD holder, employment status, and whether they are current or former healthcare workers, in addition to marital status and household monthly income. Chronic disease history was selected from a list of common diseases, and respondents were given the option to select others if their disease was not on the provided list, or to indicate that they do not have a chronic disease in case of not having a comorbidity. Additionally, they were asked to inform their smoking status and to rate their perceived health status on a five-point Likert scale ranging from very excellent to very poor and if they had prior experience with vaccine-related side effects in general. An Item related to respondent familiarity with RSV prior to the current data collection was included with four item responses ranging from “never heard of it” to “ have a good understanding”. Following that, seven questions regarding RSV knowledge were included with response options of “yes”, “No” or “Do not know”. These questions included knowing if RSV is an infectious disease, RSV transmission, high-risk groups, symptoms, complications, and whether RSV has a specific antiviral treatment. The perceived risk of contracting RSV and the severity of infection were assessed using a five-point Likert scale. Respondents were asked about their vaccination history, including items on prior uptake of indicated vaccines such as RSV, pneumococcal, seasonal influenza (any dose of influenza vaccine over the last five years), and herpes zoster, as well as the number of COVID-19 vaccine doses. Participants who reported no previous uptake of the RSV vaccine were asked about the likelihood of receiving the vaccine in the future using a five-point response format ranging from strong agreement to strong disagreement. Those who reported previous uptake, or agreement to receive the vaccine in the future, were offered a list of options that might facilitate vaccination decision, including healthcare workers’ advice, the beliefs in vaccine effectiveness and safety, or protection of self and others. Those without prior vaccination, undecided, or stating disagreement with future vaccination were shown a list of possible barriers, such as doubts about the effectiveness and safety of vaccines, conviction that the RSV risk is minimal, or the idea that the vaccine is “new” and they prefer to wait. Participants were provided the option of “others” to improve the option exhaustions for facilitators and barrier items. Finally, to identify which platform has the highest impact on participants’ decision to vaccinate, they were asked to select from a list covering physicians in primary care centers or hospitals, family, friends, social media, TV and radio or others. The questionnaire items were adopted from previously published studies and translated from English into Arabic by a bilingual study investigator; then face and content validity were assessed by three experts in the field, including consultants in family medicine, preventive medicine and a professor of public health.19,20 The calculated Cronbach’s alpha for the knowledge seven-item scale was 0.87, indicating good reliability. A pilot study was conducted with 13 participants to identify any issues and barriers to recruitment, assess the acceptability and feasibility of the study protocol, and evaluate the clarity and understanding of the study instruments. No major modifications were made, except for changing the age responses from continuous to categorical to ease data entry in the online survey and reduce female respondents’ reluctance to answer this item. Therefore, 12 of these responses (one respondent reported an age below the range indicated in the inclusion criteria) were incorporated into the main study results. Data Management and Statistical Analysis Categorical variables were summarized as frequencies and percentages. Continuous and ordinal variables were summarized as means with standard deviations (SD). Multi-response items (previous vaccinations of other indicated vaccines, RSV information sources, facilitators, barriers) were described using multiple-response frequency analysis; percentages reflect the proportion of respondents selecting each option and may sum to more than 100%. The primary outcome was RSV vaccine acceptance, transformed into a binary composite variable. A participant was classified as vaccine-acceptant if they reported (a) having already received the RSV vaccine, or (b) being willing to receive it in the future, defined as selecting “agree” or “strongly agree” on a five-point willingness Likert scale, among those who had not yet received the vaccine. All other responses (including neutral, disagree, and strongly disagree) were classified as vaccine-hesitant or undecided. To assess the relationship between predictors and RSV vaccine acceptance, data processing was performed as follows. For knowledge questions: 1 point for each correct answer; reporting no knowledge or selecting inaccurate responses was assigned 0, with a maximum possible score of 7 points, and was further categorized into low and high knowledge using the score of two as a cut-off point, where scores of 2 or higher were considered as high knowledge and low knowledge for scores <2. Additionally, the knowledge score was also presented as continuous data among vaccine acceptants and non-acceptants for unadjusted analysis. For perceived risk responses, the options of very little, little, and neutral/unsure were categorized as low perceived risk, while high and very high were classified as high perceived risk. For severity perception, very mild, mild, and moderate were classified as low perceived severity of RSV, while the high and very high were classified as high perceived severity of RSV. For the vaccine uptake composite score, we followed the method used in a previously published report,17 where each vaccine uptake was scored as one point, with a range of 0–7 points. It included the sum of COVID-19 doses (0–4) and one point for prior herpes zoster, pneumococcal, and influenza vaccination. The vaccine composite scores were presented as continuous data for vaccine acceptant and non-acceptant groups in unadjusted and adjusted analyses, and categorized as low (0–2) versus high (3–7) scores for unadjusted analyses only. Variables with an unadjusted p-value ≤ 0.20 were considered for inclusion in the multivariable logistic regression model. A two-sided p-value of < 0.05 and 95% confidence interval was used as the criterion for statistical significance throughout the analysis. All descriptive analyses were performed in IBM SPSS Statistics version 22. Ethical Approval Before initiating data collection, ethical approval was obtained from the Regional Research Ethics Committee(REC), registered at the National Committee of Bio and Med. Ethics (NCBE) Registration No. H-04-Q-001 in the Ministry of Health (MoH) branch in the Al Qassim region. Ethical approval No. 607–47-005016, on Monday, the 13th of October 2025. Informed consent was obtained from all subjects involved in the study. Results Sample Characteristics A total of 341 participants completed the survey (Table 1). The majority were aged 60–64 years (49.9%), with a quarter (25.5%) aged 70 years or above. Males comprised 57.5% of respondents. Almost all participants were Saudi nationals (97.7%), and most were married (74.5%). Educational attainment was varied: 61.9% had completed secondary education, diploma, or lower, and 38.1% held a university degree or postgraduate qualifications. Most were retired or unemployed (88.6%), and only 5.0% reported current or former healthcare worker status. Monthly household income was distributed across lower (≤10,000 SAR: 45.7%), middle (10,001–20,000 SAR: 44.0%), and higher (>20,000 SAR: 10.3%) brackets.Table 1Sociodemographic Characteristics of Study Participants (n = 341)CharacteristicFrequency%Age group 60–64 years17049.9% 65–69 years8424.6% 70–74 years4312.6% 75–79 years164.7% 80–84 years205.9% ≥85 years82.3%Sex Male19657.5% Female14542.5%Nationality Saudi33397.7% Non-Saudi82.3%Marital status Married25474.5% Widowed/single/divorced8725.5%Educational level Below university21161.9% University or higher13038.1%Employment status Retired/unemployed30288.6% Employed (governmental/private sector/private business)3911.4%Current or former healthcare worker Yes175.0% No32495.0%Household monthly income (SAR) < 5,0008224.0% 5,001–10,0007421.7% 10,001–15,0008424.6% 15,001–20,0006619.4% 20,001–25,000154.4% > 25,000205.9% Table 1Sociodemographic Characteristics of Study Participants (n = 341)CharacteristicFrequency%Age group 60–64 years17049.9% 65–69 years8424.6% 70–74 years4312.6% 75–79 years164.7% 80–84 years205.9% ≥85 years82.3%Sex Male19657.5% Female14542.5%Nationality Saudi33397.7% Non-Saudi82.3%Marital status Married25474.5% Widowed/single/divorced8725.5%Educational level Below university21161.9% University or higher13038.1%Employment status Retired/unemployed30288.6% Employed (governmental/private sector/private business)3911.4%Current or former healthcare worker Yes175.0% No32495.0%Household monthly income (SAR) < 5,0008224.0% 5,001–10,0007421.7% 10,001–15,0008424.6% 15,001–20,0006619.4% 20,001–25,000154.4% > 25,000205.9% Sociodemographic Characteristics of Study Participants (n = 341) The majority of participants (67.7%) reported at least one chronic disease, with diabetes (41.8%), and cardiovascular disease (13.9%) being the most prevalent conditions; other non-specified conditions was reported by 24.3% of respondents. Most were non-smokers (86.2%). Over half (55.9%) reported no prior receipt of any of the three indicated vaccines. Influenza vaccination was the most frequently reported (37.6%), followed by herpes zoster (18.8%), while pneumococcal vaccination was rare (0.6%). COVID-19 vaccination coverage was high, with 93.0% having received at least one dose and three doses were the most common regimen (48.1%). Self-rated health was characterized as average by 48.4% and as excellent or very excellent by 47.2%. A history of vaccine-related side effects was reported by 21.7% of participants (Table 2).Table 2Clinical and Health-Related Characteristics of Study Participants (n = 341)CharacteristicFrequency%Chronic disease status* (n = 337)Any chronic disease22867.7% Diabetes14141.8% Others8224.3% Cardiovascular disease4713.9% Asthma/chronic lung disease185.3% Autoimmune/immunosuppressive therapy133.9% No chronic disease10932.3%Smoking status Non-smoker29486.2% Ex-smoker257.3% Smoker226.5%Previous vaccination history* (n = 340) No prior indicated vaccines19055.9% Influenza vaccine (at least once in last 5 years)12837.6% Herpes zoster vaccine6418.8% Pneumococcal vaccine20.6%COVID-19 vaccination Three doses16448.1% Two doses12336.1% One dose175.0% Four doses or more133.8% Never received247.0%Self-rated health status Excellent/very excellent16147.2% Average16548.4% Poor/very poor154.4%History of vaccine-related side effects No18554.3% Do not know8224.0% Yes7421.7%Notes: *Multi-response item, as individuals could select more than one chronic disease or vaccine. Percentages are of n = 337 for the chronic disease question (four missing responses) and 340 for the previous vaccination history (one missing response). Total may exceed 100%. Table 2Clinical and Health-Related Characteristics of Study Participants (n = 341)CharacteristicFrequency%Chronic disease status* (n = 337)Any chronic disease22867.7% Diabetes14141.8% Others8224.3% Cardiovascular disease4713.9% Asthma/chronic lung disease185.3% Autoimmune/immunosuppressive therapy133.9% No chronic disease10932.3%Smoking status Non-smoker29486.2% Ex-smoker257.3% Smoker226.5%Previous vaccination history* (n = 340) No prior indicated vaccines19055.9% Influenza vaccine (at least once in last 5 years)12837.6% Herpes zoster vaccine6418.8% Pneumococcal vaccine20.6%COVID-19 vaccination Three doses16448.1% Two doses12336.1% One dose175.0% Four doses or more133.8% Never received247.0%Self-rated health status Excellent/very excellent16147.2% Average16548.4% Poor/very poor154.4%History of vaccine-related side effects No18554.3% Do not know8224.0% Yes7421.7%Notes: *Multi-response item, as individuals could select more than one chronic disease or vaccine. Percentages are of n = 337 for the chronic disease question (four missing responses) and 340 for the previous vaccination history (one missing response). Total may exceed 100%. Clinical and Health-Related Characteristics of Study Participants (n = 341) Notes: *Multi-response item, as individuals could select more than one chronic disease or vaccine. Percentages are of n = 337 for the chronic disease question (four missing responses) and 340 for the previous vaccination history (one missing response). Total may exceed 100%. RSV Familiarity, Knowledge, and Risk Perceptions RSV awareness was markedly limited in this population (Table 3). The large majority of participants (83.6%) had never heard of RSV before the survey, while 11.7% had heard of it without clear knowledge, and only 4.7% reported knowing some facts or having a good understanding. Correspondingly, correct response rates across the seven knowledge items were uniformly low, ranging from 4.1% for the item on the absence of specific pharmacological treatments for RSV (K3), to 28.4% for recognition of the elderly as a high-risk group (K7). Fewer than one in five participants correctly identified RSV as a respiratory infectious disease (15.8%), described its mode of transmission (19.9%), recognized its characteristic symptoms (15.0%), or knew it could cause bronchiolitis and pneumonia (18.2%).Table 3RSV Familiarity, Knowledge, and Risk Perceptions (n = 341)CharacteristicFrequency%RSV familiarity before this surveyNever heard of RSV28583.6% Heard of it but do not know what it is4011.7% Know some facts about RSV154.4% Have a good understanding of RSV10.3%RSV knowledge items, n (%) answering correctly (n = 341)* RSV is a respiratory infectious disease5415.8% RSV is transmitted by droplet and contact6819.9% Specific drugs exist to treat RSV144.1% Symptoms include cough, runny nose, and sneezing5115.0% RSV can cause bronchiolitis and pneumonia6218.2% Infants and young children are a high-risk group5215.2% Elderly people are a high-risk group9728.4%Perceived likelihood of contracting RSV infection Very unlikely/unlikely9327.3% Neutral23468.6% Likely/very likely144.1%Perceived severity of RSV infection Very mild/mild13038.1% Moderate17049.9% High/very high4112.0%Notes: *For K3, the correct response is “No” (there are currently no specific pharmacological treatments for RSV infection). For the other six questions, the correct response was “Yes”. “Don’t know” responses were scored as incorrect for all items. Table 3RSV Familiarity, Knowledge, and Risk Perceptions (n = 341)CharacteristicFrequency%RSV familiarity before this surveyNever heard of RSV28583.6% Heard of it but do not know what it is4011.7% Know some facts about RSV154.4% Have a good understanding of RSV10.3%RSV knowledge items, n (%) answering correctly (n = 341)* RSV is a respiratory infectious disease5415.8% RSV is transmitted by droplet and contact6819.9% Specific drugs exist to treat RSV144.1% Symptoms include cough, runny nose, and sneezing5115.0% RSV can cause bronchiolitis and pneumonia6218.2% Infants and young children are a high-risk group5215.2% Elderly people are a high-risk group9728.4%Perceived likelihood of contracting RSV infection Very unlikely/unlikely9327.3% Neutral23468.6% Likely/very likely144.1%Perceived severity of RSV infection Very mild/mild13038.1% Moderate17049.9% High/very high4112.0%Notes: *For K3, the correct response is “No” (there are currently no specific pharmacological treatments for RSV infection). For the other six questions, the correct response was “Yes”. “Don’t know” responses were scored as incorrect for all items. RSV Familiarity, Knowledge, and Risk Perceptions (n = 341) Notes: *For K3, the correct response is “No” (there are currently no specific pharmacological treatments for RSV infection). For the other six questions, the correct response was “Yes”. “Don’t know” responses were scored as incorrect for all items. Perceived personal risk of RSV infection was predominantly neutral (68.6%), with only 4.1% perceiving their risk as high or very high. Perceived severity was rated moderate by 49.9% of participants; 12.0% regarded the potential illness as highly or very highly severe. RSV Vaccine Acceptance Prior receipt of the RSV vaccine was reported by only five participants (1.5%; Table 4). Among the 336 non-recipients with valid willingness data, 50 (14.7% of the total 341 respondents) indicated they would agree or strongly agree to receive the vaccine in the future, while 219 (64.2%) were neutral or undecided, 30 (8.8%) disagreed, and 37 (10.9%) strongly disagreed. Combining prior recipients with future-willing non-recipients, the overall RSV vaccine acceptance rate was 55 of 341 participants (16.1%), with the remaining 286 (83.9%) classified as vaccine-hesitant or undecided.Table 4RSV Vaccine Acceptance Outcomes and Most Influential Information Sources (n = 341)CharacteristicFrequency%Prior RSV vaccine receipt (n = 341) Yes51.5% No33698.5%Future willingness to receive RSV vaccine among non-recipients (n = 336); (% of the total sample) Strongly agree216.2% Agree298.5% Neutral21964.2% Disagree308.8% Strongly disagree3710.9%Combined RSV vaccine acceptance (n = 341) Vaccine acceptant5516.1% Vaccine-hesitant or undecided28683.9%Most influential source for RSV vaccine recommendation* (n = 341) Physicians in primary healthcare/hospitals20058.7% Family members10229.9% Friends8324.3% Social media platforms5716.7% Other319.1% Radio and television113.2%Notes: *Multi-response item; respondents could select up to five sources or others option. Counts represent the total number of respondents selecting each source across all ranking positions. Table 4RSV Vaccine Acceptance Outcomes and Most Influential Information Sources (n = 341)CharacteristicFrequency%Prior RSV vaccine receipt (n = 341) Yes51.5% No33698.5%Future willingness to receive RSV vaccine among non-recipients (n = 336); (% of the total sample) Strongly agree216.2% Agree298.5% Neutral21964.2% Disagree308.8% Strongly disagree3710.9%Combined RSV vaccine acceptance (n = 341) Vaccine acceptant5516.1% Vaccine-hesitant or undecided28683.9%Most influential source for RSV vaccine recommendation* (n = 341) Physicians in primary healthcare/hospitals20058.7% Family members10229.9% Friends8324.3% Social media platforms5716.7% Other319.1% Radio and television113.2%Notes: *Multi-response item; respondents could select up to five sources or others option. Counts represent the total number of respondents selecting each source across all ranking positions. RSV Vaccine Acceptance Outcomes and Most Influential Information Sources (n = 341) Notes: *Multi-response item; respondents could select up to five sources or others option. Counts represent the total number of respondents selecting each source across all ranking positions. Physicians in primary healthcare and hospital settings were identified as the most influential source for vaccine recommendation by 58.7% of respondents, followed by family members (29.9%), friends (24.3%), and social media platforms (16.7%) (Table 4). Facilitators and Barriers Among the 55 vaccine-acceptant participants, the most commonly cited reasons for acceptance were healthcare professional recommendation (45.5%), concern about personal risk of RSV infection (43.6%), confidence in vaccine safety (41.8%), and the motivation to protect others (40.0%). Perceived disease severity (30.9%) and belief in vaccine effectiveness (25.5%) were additional facilitators (Figure 1). Figure 1Facilitators of RSV vaccine acceptance among acceptant respondents (n = 55). Multi-response item; respondents could select more than one facilitator. Percentages are of acceptant respondents.A horizontal bar graph showing facilitators of RSV vaccine acceptance among acceptant respondents. Facilitators of RSV vaccine acceptance among acceptant respondents (n = 55). Multi-response item; respondents could select more than one facilitator. Percentages are of acceptant respondents. Among the 286 hesitant or undecided participants, the most prevalent barrier was caution toward receiving a newly approved vaccine (“want to wait”; 50.0%), followed by concerns about vaccine safety or side effects (44.1%), and doubts about vaccine effectiveness (26.2%). Additional barriers included other unspecified reasons (15.0%), perceived absence of personal risk (15.0%), and health problems or contraindications (10.5%) (Figure 2). Figure 2Barriers to RSV vaccine acceptance among hesitant or undecided respondents (n = 286). Multi-response item; respondents could select more than one barrier. Percentages are of non-acceptant respondents.A horizontal bar graph showing barriers to respiratory syncytial virus vaccine acceptance among non-acceptants respondents. Barriers to RSV vaccine acceptance among hesitant or undecided respondents (n = 286). Multi-response item; respondents could select more than one barrier. Percentages are of non-acceptant respondents. Univariable Analyses Unadjusted analyses examined associations between candidate predictors and RSV vaccine acceptance (Table 5). Sex was the only sociodemographic variable to reach statistical significance: male participants had a higher acceptance rate than females (19.9% vs 11.0%; cOR 2.004, 95% CI 1.071–3.745, p = 0.030). Marital status (married vs others; p = 0.177) and educational level (university or above vs below; p = 0.129) met the p ≤ 0.20 threshold. Additionally, employment status (working vs retired/unemployed; p = 0.091), nationality (p = 0.115), have met the p-value threshold. Vaccine uptake composite score was significant in univariable analysis (mean ± SD: 3.56 ± 1.21 vs 2.81 ± 1.28; cOR per 1-point increase 1.638, 95% CI 1.272–2.109, p < 0.001). Nationality was excluded from the adjusted model despite meeting the threshold due to the very small non-Saudi subsample (n = 8). Knowledge, perceived susceptibility, and severity did not meet the p-value threshold. For exploratory analysis purposes, the authors assessed these three predictors among only those with previous awareness of RSV (n=56) and found no significant association with RSV acceptance and produced a wide confidence interval.Table 5Univariable and Multivariable Logistic Regression Analyses of Factors Associated with RSV Vaccine Acceptance (N = 341)Variablen/N (%) acceptantCrude OR (95% CI)paORa (95% CI)pAge group < 70 years*40/254 (15.7%) ≥ 70 years15/87 (17.2%)1.115 (0.581–2.137)0.744Sex Female*16/145 (11.0%) Male39/196 (19.9%)2.004 (1.071–3.745)0.0301.652 (0.805–3.392)0.171Nationality b Non-Saudi*3/8 (37.5%) Saudi52/333 (15.6%)0.308 (0.072–1.330)0.115Marital status c Single/Widowed/Divorced*10/87 (11.5%) Married45/254 (17.7%)1.658 (0.796–3.448)0.1770.920 (0.400–2.113)0.844Educational level d Below university*29/211 (13.7%) University or above26/130 (20.0%)1.569 (0.877–2.807)0.1291.234 (0.653–2.330)0.517Employment status Working*10/39 (25.6%) Retired or unemployed45/302 (14.9%)0.508 (0.231–1.114)0.0910.634 (0.283–1.418)0.267Healthcare worker status No*51/324 (15.7%) Yes4/17 (23.5%)1.647 (0.516–5.263)0.399Household monthly income (SAR) 10,001–20,000*24/150 (16.0%) ≤ 10,00026/156 (16.7%)1.050 (0.573–1.926)0.875 > 20,0005/35 (14.3%)0.875 (0.308–2.482)0.802Smoking status Ex-smoker/non-smoker*52/319 (16.3%) Smoker3/22 (13.6%)0.811 (0.231–2.841)0.743Self-rated health status Excellent/very excellent*28/161 (17.4%) Average/poor27/180 (15.0%)0.838 (0.471–1.493)0.549Chronic disease status (n = 337) No chronic disease*18/109 (16.5%) Has chronic disease36/228 (15.8%)0.948 (0.511–1.759)0.865Previous vaccine side effects history No / do not know*45/267 (16.9%) Yes10/74 (13.5%)0.771 (0.368–1.616)0.490 Vaccine uptake composite score (0–7)**3.56 ± 1.21 vs 2.81 ± 1.281.638 (1.272–2.109)< 0.0011.575 (1.220–2.033)< 0.001Vaccine uptake level Score 0–2 (lower uptake)*10/116 (8.6%) Score 3–7 (higher uptake)45/225 (20.0%)2.652 (1.282–5.464)0.009Prior RSV awareness Never heard of RSV*45/285 (15.8%) Any prior awareness10/56 (17.9%)1.159 (0.545–2.463)0.701 RSV knowledge score (0–7)1.44 ± 2.15 vs 1.12 ± 1.871.084 (0.943–1.248)0.257 RSV knowledge level Low knowledge level*38/248 (15.3%) High knowledge level17/93 (18.3%)1.236 (0.659–2.319)0.509Perceived susceptibility to RSV Low perception*51/327 (15.6%) High perception4/14 (28.6%)2.165 (0.654–7.143)0.206Perceived seriousness of RSV Low perception*47/300 (15.7%) High perception8/41 (19.5%)1.305 (0.568–3.003)0.531Notes: Bold p-values are statistically significant at p < 0.05. *Represents the reference value a aOR = adjusted odds ratio from multivariable binary logistic regression. b Nationality met the p ≤ 0.20 unadjusted threshold but was excluded from the adjusted model due to the sparse non-Saudi cell (n = 8); crude OR reported for completeness only. c Marital status recoded: married vs single/widowed/divorced (reference). d Educational level recoded: university degree or above vs below university (reference); diploma classified as below university.**Vaccine uptake composite score (0–7): sum of COVID-19 doses (0–4) and binary indicators for prior herpes zoster, pneumococcal, and influenza vaccination. Mean ± SD is shown for the acceptant vs hesitant groups for continuous predictors, along with high and low categories for the knowledge and vaccine composite scores. Table 5Univariable and Multivariable Logistic Regression Analyses of Factors Associated with RSV Vaccine Acceptance (N = 341)Variablen/N (%) acceptantCrude OR (95% CI)paORa (95% CI)pAge group < 70 years*40/254 (15.7%) ≥ 70 years15/87 (17.2%)1.115 (0.581–2.137)0.744Sex Female*16/145 (11.0%) Male39/196 (19.9%)2.004 (1.071–3.745)0.0301.652 (0.805–3.392)0.171Nationality b Non-Saudi*3/8 (37.5%) Saudi52/333 (15.6%)0.308 (0.072–1.330)0.115Marital status c Single/Widowed/Divorced*10/87 (11.5%) Married45/254 (17.7%)1.658 (0.796–3.448)0.1770.920 (0.400–2.113)0.844Educational level d Below university*29/211 (13.7%) University or above26/130 (20.0%)1.569 (0.877–2.807)0.1291.234 (0.653–2.330)0.517Employment status Working*10/39 (25.6%) Retired or unemployed45/302 (14.9%)0.508 (0.231–1.114)0.0910.634 (0.283–1.418)0.267Healthcare worker status No*51/324 (15.7%) Yes4/17 (23.5%)1.647 (0.516–5.263)0.399Household monthly income (SAR) 10,001–20,000*24/150 (16.0%) ≤ 10,00026/156 (16.7%)1.050 (0.573–1.926)0.875 > 20,0005/35 (14.3%)0.875 (0.308–2.482)0.802Smoking status Ex-smoker/non-smoker*52/319 (16.3%) Smoker3/22 (13.6%)0.811 (0.231–2.841)0.743Self-rated health status Excellent/very excellent*28/161 (17.4%) Average/poor27/180 (15.0%)0.838 (0.471–1.493)0.549Chronic disease status (n = 337) No chronic disease*18/109 (16.5%) Has chronic disease36/228 (15.8%)0.948 (0.511–1.759)0.865Previous vaccine side effects history No / do not know*45/267 (16.9%) Yes10/74 (13.5%)0.771 (0.368–1.616)0.490 Vaccine uptake composite score (0–7)**3.56 ± 1.21 vs 2.81 ± 1.281.638 (1.272–2.109)< 0.0011.575 (1.220–2.033)< 0.001Vaccine uptake level Score 0–2 (lower uptake)*10/116 (8.6%) Score 3–7 (higher uptake)45/225 (20.0%)2.652 (1.282–5.464)0.009Prior RSV awareness Never heard of RSV*45/285 (15.8%) Any prior awareness10/56 (17.9%)1.159 (0.545–2.463)0.701 RSV knowledge score (0–7)1.44 ± 2.15 vs 1.12 ± 1.871.084 (0.943–1.248)0.257 RSV knowledge level Low knowledge level*38/248 (15.3%) High knowledge level17/93 (18.3%)1.236 (0.659–2.319)0.509Perceived susceptibility to RSV Low perception*51/327 (15.6%) High perception4/14 (28.6%)2.165 (0.654–7.143)0.206Perceived seriousness of RSV Low perception*47/300 (15.7%) High perception8/41 (19.5%)1.305 (0.568–3.003)0.531Notes: Bold p-values are statistically significant at p < 0.05. *Represents the reference value a aOR = adjusted odds ratio from multivariable binary logistic regression. b Nationality met the p ≤ 0.20 unadjusted threshold but was excluded from the adjusted model due to the sparse non-Saudi cell (n = 8); crude OR reported for completeness only. c Marital status recoded: married vs single/widowed/divorced (reference). d Educational level recoded: university degree or above vs below university (reference); diploma classified as below university.**Vaccine uptake composite score (0–7): sum of COVID-19 doses (0–4) and binary indicators for prior herpes zoster, pneumococcal, and influenza vaccination. Mean ± SD is shown for the acceptant vs hesitant groups for continuous predictors, along with high and low categories for the knowledge and vaccine composite scores. Univariable and Multivariable Logistic Regression Analyses of Factors Associated with RSV Vaccine Acceptance (N = 341) Notes: Bold p-values are statistically significant at p < 0.05. *Represents the reference value a aOR = adjusted odds ratio from multivariable binary logistic regression. b Nationality met the p ≤ 0.20 unadjusted threshold but was excluded from the adjusted model due to the sparse non-Saudi cell (n = 8); crude OR reported for completeness only. c Marital status recoded: married vs single/widowed/divorced (reference). d Educational level recoded: university degree or above vs below university (reference); diploma classified as below university.**Vaccine uptake composite score (0–7): sum of COVID-19 doses (0–4) and binary indicators for prior herpes zoster, pneumococcal, and influenza vaccination. Mean ± SD is shown for the acceptant vs hesitant groups for continuous predictors, along with high and low categories for the knowledge and vaccine composite scores. Multivariable Analyses Five predictors (sex, marital status, educational level, employment status, and vaccine uptake composite score) were entered into a multivariable logistic model (Table 5). The vaccine uptake composite score was the only statistically significant independent predictor of RSV vaccine acceptance in the models (aOR 1.575, 95% CI 1.220–2.033, p < 0.001). Each additional point on the composite score, reflecting greater prior engagement with clinically recommended vaccinations, was associated with approximately 58% higher odds of acceptance after adjustment. Exploratory univariable analysis in Supplementary Table 1 shows that previous uptake of influenza or Herpes zoster contributed the most to RSV acceptance. Male sex showed a trend toward higher acceptance that did not reach statistical significance following adjustment (aOR 1.652, 95% CI 0.805–3.392, p = 0.171). Marital status, educational level, and employment status were not independently associated with acceptance in either model (all had p > 0.05). Discussion The current study is among the first in Saudi Arabia and the Arab world to assess RSV vaccine acceptance among older adults following its recent approval and introduction. The study reveals very low acceptance and coverage rates of 16.1% and 1.5%, respectively. This is much lower than in the United States (USA), where coverage exceeds 31% among high-risk adults aged 50-74 years and 42% among adults aged 75 years and older. Compared with the USA rates, a sample of Latinos living in the USA and Japanese elderly revealed substantially lower uptake of 3% and 4.2%, respectively.21–23 Data from Arab countries remains limited; one study included participants aged 50 years and above, demonstrated a higher acceptance of 51.1% in total, and substantially higher acceptance among 51 sampled Saudi (70.6%) compared to the current study; however, that study’s comparability is limited by including a smaller number of participants from Saudi Arabia and wider age groups while the current indication in Saudi Arabia begins at the age of 60 years.17,24 The current study shows that the majority of non-vaccinated individuals were neutral or undecided (64.2% of the total sample). Among the Arab population, those who were “neutral” toward the willingness to vaccinate constituted a notably lower proportion (22.4%), with higher awareness of the RSV (though still low) than in the current study population (less than 5% knew some facts about the RSV).17 These observations may indicate information-related barriers rather than informed refusal of the vaccine, given that the majority were unaware of RSV prior to the study and the community tendency to make vaccination decisions based on the informed advice of public health authorities or healthcare workers. This represents an area of improvement and is in line with the observed lack of knowledge of RSV infection among the elderly observed in the current study, which is substantially higher than in other populations, such as postpartum women.18 Therefore, labeling them as hesitant may not reflect the full picture, and other terms can be used, such as undecided or unsure, for a more cautious interpretation. Addressing Health Belief Model components, such as perceived risk and severity, expected benefits, and self-efficacy, is often an important contributor to vaccine acceptance for several adult vaccines, including COVID-19, seasonal influenza, pneumococcal, and zoster vaccines.25–28 In our study, perceived susceptibility and severity of RSV did not show a significant association with vaccine acceptance. This may be due to the majority of participants reporting no prior or limited knowledge of RSV, with substantial responses to knowledge questions being “do not know” rather than “yes” or “no” responses; thereby making it difficult to assess the risks of RSV exposure accurately. Among the Chinese population, prior knowledge of RSV contributed to higher perceived susceptibility, which impacted vaccine acceptance.20 Elevated risk and severity perception, higher self-efficacy, perceived benefits, and lower barriers have been shown to be associated with higher intent.20,29 Consistent with these reports, Japanese elderly with higher knowledge of the clinical picture and severity of RSV demonstrated higher vaccination rates.23 In line with this trend, it was also noted that lower knowledge and perceived risk were associated with lower uptake of Zoster vaccines among the Saudi population.30 Therefore, accurate risk communication by public health authorities may be needed to enhance perceptions of RSV risk and related severe respiratory disease among the targeted group. Sociodemographic variables exhibit inconsistent contributions to vaccine acceptance across vaccines and populations. In the current study, none of the included variables showed a significant association in the adjusted analysis, with being male demonstrating elevated acceptance in univariable analysis, in line with Arab countries’ findings, where males tended to have a positive attitude toward the RSV vaccine.17 Additionally, among the elderly in the USA, the uptake is noted to be higher among individuals with higher incomes and education.31 A possible explanation is that with the introduction of a new vaccine, males usually have a lower level of fear and safety concerns compared to females, in line with higher male acceptance reported before the COVID-19 vaccine release in the United States,32 and after the releases in several countries,33 and similar to higher male acceptance reported with the Zoster vaccine in the Al-Qassim region in Saudi Arabia.34 Healthcare worker recommendations are a well-known factor in improving vaccine coverage, as observed in various vaccine studies. The most frequently reported contributor to vaccine acceptance was physician advice, highlighting the role of physicians’ advice in improving knowledge and changing older adults’ behavior. A similar trend is observed with the recently initiated Zoster vaccines in and outside Saudi Arabia, along with a similar effect noted for influenza and pneumococcal vaccination,30,34–36 as trust in physicians has been shown to boost vaccine confidence.22 The impact of a physician in delivering vaccine recommendations to older adults may be greater than in other age groups, given their frequent encounters with the healthcare system and a greater need to control comorbid conditions and access preventive services. However, previous reports indicated physicians may have a lower perceived burden of RSV among the elderly compared to infants, limiting their recognition and support of RSV immunization.37 Therefore, enhancing physicians’ knowledge of RSV risks among the elderly and addressing their role in vaccine recommendations for the elderly are essential to improve vaccine coverage. Additionally, a prior report among Arab individuals indicated that exhibiting information needs regarding vaccines was positively associated with vaccine acceptance.17 Prior vaccination is documented as a facilitator of vaccine uptake in general; this was also observed in the current report models (aOR 1.575, 95% CI 1.220–2.033, p < 0.001), in line with the Arab population, where higher coverage with other indicated vaccines like pneumococcal, herpes zoster, COVID-19 and seasonal influenza were associated with RSV vaccine acceptance and in line with USA data where uptake of non-RSV vaccine was shown to be the strongest predictor of RSV coverage.17,31 Consistent with these reports, pregnant women who received HPV or tetanus vaccines were more likely to receive the maternal RSV vaccine to protect their infant.38,39 Surprisingly, when comparing other indicated vaccines with RSV, pneumococcal uptake was lower, even though it was introduced before both RSV and HZV in Saudi Arabia among the older age group. This could be a result of the Ministry of Health’s current campaign and the elderly’s knowledge of eligibility, which appears to be more focused on influenza and HZV vaccines. As previously reported, confidence in vaccine safety and the elderly’s knowledge of their eligibility for vaccination serve as strong facilitators of vaccination.22,23,35 Though the RSV vaccine may face challenges with being new and limited knowledge compared to the long-existing flu vaccine, it has the advantage of requiring a single shot, according to the current recommendation, unlike the need for annual adherence with the seasonal influenza vaccine. Co-administration with other indicated vaccines, such as pneumococcal or seasonal influenza, may help improve coverage and decrease costs and unnecessary healthcare system encounters, as a significant number of elderly presenting to the healthcare system without being offered the RSV vaccine may represent missed opportunities for vaccination, as reports showed that about 67.3% of elderly receiving seasonal influenza vaccine did not receive the RSV vaccine.31 Nevertheless, previous reports have demonstrated an acceptable safety profile and effectiveness of RSV when co-administered with COVID-19, seasonal influenza, and 20-valent pneumococcal vaccine.40–42 The RSV vaccine is provided free of charge for locals in Saudi Arabia, and individuals can book a vaccination appointment through a mobile application.24 This raises the potential for improving vaccine coverage as it increases accessibility and mitigates financial cost associated with out-of-pocket fees, not having health insurance, or lower income, which may serve as a negative contributor to uptake of several vaccines, as shown with pneumococcal, shingles, and other vaccines.43–45 Furthermore, Saudi Arabia, in particular, and other Arab countries are characterized by increased engagement of family members in elderly care, including appointment scheduling for treatment and preventive services.46,47 This trend is noted among the Latino population in the USA.22 Therefore, addressing caregivers during public health campaigns may provide additional support for older adults’ vaccination, including but not limited to the RSV vaccine. The current study is among the first to estimate uptake of the recently introduced RSV vaccine among the indicated older adult population in Saudi Arabia, as well as future acceptance and cited barriers. Additionally, it reports information on other vaccines indicated for this high-risk group. However, it faced several challenges, including those inherent to the study design, such as the cross-sectional approach, which limits causal interpretation because it lacks temporal sequencing to determine whether certain predictors precede certain practices, such as vaccine acceptance. The uptake information relies on self-reported data rather than electronic health records, which makes it prone to recall bias. The sampling followed a non-probability approach through an online survey, which may affect the representativeness of the study population; for example, older adults with limited access to the internet, low digital literacy, low socioeconomic status, reduced family support or impaired cognitive function may have a lower tendency to participate compared to individuals not having these constraints, as a result of selection or volunteer bias. Therefore, in addition to the elderly themselves, family members were permitted to respond on behalf of the eligible elderly parent to improve access for adults with limited digital literacy, which may lead to misclassification of subjective measures such as knowledge, risk perception, and future intent. Additionally, online recruitment may also cluster responses within certain families or communities, which in turn affects the representativeness or generalizability of the study findings to the population of the Al-Qassim region. The current report recruited participants from a single region of the country, which may also limit the generalizability of the study’s findings to other regions. The relatively small sample may not fully capture the acceptance among the older adult population of the region. It may also limit the precision of reported acceptance and reduce the power to detect associations, although the low levels of acceptance and uptake are unlikely to be explained by limited sample size alone. Because a large number of participants were unsure regarding their future willingness to vaccinate and the aforementioned limitations, cautious interpretation is warranted. Future studies should include probability sampling across different regions with larger samples, electronic health record verification of vaccine uptake, and interview-based data collection to reach older adults with limited digital literacy. Serial cross-sectional studies would help detect changes in vaccine acceptance over time as more information reaches the population. Nevertheless, the current study provides insight and informs policy on RSV and other vaccine acceptance among older adults in Saudi Arabia, along with related facilitators and barriers of acceptance. Conclusions The study demonstrated very low vaccine uptake and intent, associated with low awareness, concerns about the vaccine’s recent introduction, and uncertainty towards its safety and effectiveness. Informing the older adult population and their caregivers regarding their eligibility and the importance of vaccines is likely to improve coverage. Healthcare worker vaccine recommendations and accurate risk communication have been demonstrated to be prevalent facilitators of vaccine acceptance. Prior vaccination with other indicated vaccines has been associated with improved coverage, highlighting possible cross-vaccine hesitancy and the need to address this issue across indicated vaccines, as they may share similar concerns. Future studies may include additional regions of the country with larger samples, with repeated serial cross-sectional studies to demonstrate the trend in RSV uptake over time and across regions.